The DOI matches its Crossref record; 131 of the 149 references it cites were found in a registry or an index, and 5 are not checked yet.
Accelerated COVID-19 vaccine development: milestones, lessons, and prospects
Open accessAbstract
The development of effective vaccines to combat infectious diseases is a complex multi-year and multi-stakeholder process. To accelerate the development of vaccines for coronavirus disease 2019 (COVID-19), a novel pathogen emerging in late 2019 and spreading globally by early 2020, the United States government (USG) mounted an operation bridging public and private sector expertise and infrastructure. The success of the endeavor can be seen in the rapid advanced development of multiple vaccine candidates, with several demonstrating efficacy and now being administered around the globe. Here, we review the milestones enabling the USG-led effort, the methods utilized, and ensuing outcomes. We discuss the current status of COVID-19 vaccine development and provide a perspective for how partnership and preparedness can be better utilized in response to future public-health pandemic emergencies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“mRNA vaccines are promising alternatives to conventional vaccines because of their high potency, low manufacturing cost, and short preparation period (Bok et al., 2021; Chaudhary et al., 2021).”
From A novel Toxoplasma gondii TGGT1_316290 mRNA-LNP vaccine elicits protective immune response against toxoplasmosis in mice (2023) · cites this paper as Bok et al., 2021
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Vahidy, F., Pischel, L., Tano, M., Pan, A. P., Boom, M. L., Sostman, H. D., Nasir, K., & Omer, S. B. (2021) · medRxiv · doi:10.1101/2021.04.21.21255873 · Cited by 18
RetractedSafety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592 · cited 2×
“Pfizer/BioNTech conducted their phase 3 efficacy trial in 150 sites around the world, including those in the United States, Argentina, Brazil, South Africa, Germany, and Turkey (Pfizer, 2020a, 2020b; Polack et al., 2020).”
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine
Baden, L. R., El Sahly, H. M., Essink, B., Kotloff, K., Frey, S., Novak, R., Diemert, D., Spector, S. A., Rouphael, N., Creech, C. B., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2035389 · Cited by 10,119
Self-citationCryo-EM structure of the 2019-nCoV spike in the prefusion conformation
Wrapp, D., Wang, N., Corbett, K. S., Goldsmith, J. A., Hsieh, C.-L., Abiona, O., Graham, B. S., & McLellan, J. S. (2020) · Science · doi:10.1126/science.abb2507 · Cited by 8,897
Self-citationFirst case of 2019 novel coronavirus in the United States
Holshue, M. L., DeBolt, C., Lindquist, S., Lofy, K. H., Wiesman, J., Bruce, H., Spitters, C., Ericson, K., Wilkerson, S., Tural, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2001191 · Cited by 6,030
Pushko, P., Pumpens, P., & Grens, E. (2013) · Intervirology · doi:10.1159/000346773 · Cited by 5,975
mRNA vaccines — a new era in vaccinology
Pardi, N., Hogan, M. J., Porter, F. W., & Weissman, D. (2018) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2017.243 · Cited by 4,667
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report
Jackson, L. A., Anderson, E. J., Rouphael, N. G., Roberts, P. C., Makhene, M., Coler, R. N., McCullough, M. P., Chappell, J. D., Denison, M. R., Stevens, L. J., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2022483 · Cited by 3,237
Self-citationEffectiveness of Covid-19 Vaccines against the B.1.617.2 (Delta) Variant
Lopez Bernal, J., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2108891 · Cited by 2,889
Effectiveness of COVID-19 vaccines against the B.1.617.2 variant
Bernal, J. L., Andrews, N., Gower, C., Gallagher, E., Simmons, R., Thelwall, S., Stowe, J., Tessier, E., Groves, N., Dabrera, G., et al. (2021) · doi:10.1101/2021.05.22.21257658 · Cited by 2,888 · cited 2×
“While most immunocompromised individuals were ineligible for the phase 3 efficacy Sponsor Real-world vaccine effectiveness against prototype SARSCoV-2 strain Real-world vaccine effectiveness against SARS-CoV-2 variants Alpha (B.1.1.7) Beta (B.1.351) Gamma (P.1) Delta (B.1.617.2) I/SI SD I/SI SD I/SI SD I/SI SD Pfizer/…”
BackgroundInfluential
Research works printed but not linked: 5
- Andrejko, 2021, Early evidence of COVID-19 vaccine effectiveness within the general population of California, medRxiv
- Barouch, 2021, Durable Humoral and Cellular Immune Responses Following Ad26.COV2.S Vaccination for COVID-19, medRxiv
- Swift, 2021, Effectiveness of mRNA COVID-19 vaccines against SARS-CoV-2 infection in a cohort of healthcare personnel, Clin. Infect. Dis.
- Tande, 2021, Impact of the COVID-19 Vaccine on Asymptomatic Infection Among Patients Undergoing Pre-Procedural COVID-19 Molecular Screening, Clin. Infect. Dis.
- Walsh, 2020, Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates, N. Engl. J. Med., 383, 2439, 10.1056/NEJMoa2027906 · DOI · Paper page
Cited by
Sorted by citations
Cromer, D., Steain, M., Reynaldi, A., Schlub, T. E., Wheatley, A. K., Juno, J. A., Kent, S. J., Triccas, J. A., Khoury, D. S., & Davenport, M. P. (2022) · The Lancet Microbe · doi:10.1016/s2666-5247(21)00267-6 · Cited by 590
Harnessing the microbiome to prevent global biodiversity loss
Peixoto, R. S., Voolstra, C. R., Sweet, M. J., Duarte, C. M., Carvalho, S., Villela, H., Lunshof, J. E., Gram, L., Woodhams, D. C., Walter, J., et al. (2022) · Nature Microbiology · doi:10.1038/s41564-022-01173-1 · Cited by 284
COVID-19 Vaccination Hesitancy among Healthcare Workers—A Review
Peterson, C., Lee, B. D., & NUGENT, K. M. (2022) · Vaccines · doi:10.3390/vaccines10060948 · Cited by 232
Menstrual Symptoms After COVID-19 Vaccine: A Cross-Sectional Investigation in the MENA Region
Muhaidat, N., Alshrouf, M. A., Azzam, M., Karam, A. M., Al-Nazer, M., & Al-Ani, A. (2022) · International Journal of Women s Health · doi:10.2147/ijwh.s352167 · Cited by 168
Yang, Z.-R., Jiang, Y.-W., Li, F.-X., Liu, D., Lin, T.-F., Zhao, Z.-Y., Wei, C., Jin, Q.-Y., Li, X.-M., Jia, Y.-X., et al. (2023) · The Lancet Microbe · doi:10.1016/s2666-5247(22)00390-1 · Cited by 138
Metadata
- Authors
- Bok, K., Sitar, S., Graham, B. S., & Mascola, J. R.
- Affiliations
- National Institutes of Health (US)
- Corresponding author
- Mascola, John R.
- Venue
- Immunity
- Publisher
- Elsevier BV
- Published
- 2021-08
- Volume
- 54
- Issue
- 8
- Pages
- 1636-1651
- ISSN
- 1074-7613 (ISSN-L)
- PMC
- PMC8328682
- OpenAlex
- W3187496430
- Cited by
- 254
- References
- 149
- Citations by year
- 2026: 9 · 2025: 36 · 2024: 46 · 2023: 74 · 2022: 77 · 2021: 12
- FWCI
- 6.11
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- Locations
- Immunity (publishedVersion, cc-by-nc-nd)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- U.S. Department of Health and Human Services (63/140,250, PCT/US2021/017709, WO/2018/081318)
- Centers for Disease Control and Prevention
- National Institute of Allergy and Infectious Diseases
- Biomedical Advanced Research and Development Authority
- National Institutes of Health
- Topics
- Health Sciences › Medicine › Infectious Diseases › SARS-CoV-2 and COVID-19 Research
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Legal, Health, Environmental and COVID-19 Challenges
- Social Sciences › Health › Vaccine Coverage and Hesitancy
- Keywords
- COVID-19 vaccine development, SARS-CoV-2, public-private partnerships, vaccine candidate, pandemic preparedness, public health emergencies, vaccine efficacy
- MeSH terms
- Vaccination Coverage, Vaccinology, COVID-19, SARS-CoV-2, COVID-19 Vaccines, Biotechnology, Humans, Models, Molecular, Research, United States, Outcome Assessment, Health Care, Bioengineering, Public Health Surveillance
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
